The device focuses on examining sonoporation-based drug delivery that involves ultrasound-based treatment with microbubbles.

The upcoming report from Abbott (ABT) is expected to reveal quarterly earnings of $1.25 per share, indicating an increase of 9.7% compared to the year-ago period. Analysts forecast revenues of $11.07 ...

Abbott Laboratories ABT is slated to report second-quarter 2025 results on July 17, before the opening bell. The company delivered adjusted earnings per share (EPS) of $1.09 in the last quarter, which ...

According to Abbott, people with movement disorders will travel over 150 miles on average to visit specialists in deep brain stimulation. "We are continuing to make these kinds of investments and ...

Abbott Laboratories ABT has been delivering consistent organic growth in the Established Pharmaceuticals Division (EPD) and Diabetes segments. However, the soft neuromodulation business is a ...

Abbott's Neuromodulation group has created an app called the NeuroSphere Virtual Clinic, which allows patients with chronic pain who use spinal cord or dorsal root ganglion stimulators to have ...

Global neuromodulation market is poised to grow by USD 5.2 billion during 2020-2024, progressing at a CAGR of more than 11%, ... Major Five Neuromodulation Market Companies: Abbott Laboratories.

Abbott has signed on to the wide-ranging neuroscience project run by the National Institutes of Health, pledging to provide its neuromodulation tech for the public-private research effort.

It actually undergirds many of Abbott's most significant revenue franchises in 2021; these include its ~$14.3 billion medical device portfolio (heart, diabetes, neuromodulation), and its $6.6 ...